In today’s rapidly evolving diagnostic landscape, labs are under immense pressure to provide results that are both immediate and reliable. This has created a fundamental conundrum: should labs be empowered to create their own tests to meet urgent patient needs, or is the rigorous—and often time-consuming—process of FDA review a non-negotiable necessity for safety?
To answer this, we must first understand the divide between traditional manufacturing and the modern clinical lab, and how the recent legal battles have reshaped the future of patient care.
LDTs vs FDA-Regulated Tests
Laboratory Developed Tests (LDTs) and FDA-regulated tests differ fundamentally in where they are made and how they are overseen.
- LDTs are designed, manufactured, and used entirely within a single laboratory facility. Because they are viewed as a professional service provided by clinicians, they have traditionally been regulated under CLIA (Clinical Laboratory Improvement Amendments), which focuses on the quality of the lab’s personnel and processes.
- FDA-cleared tests are finished products or “kits” manufactured by device companies and sold to multiple labs. These undergo rigorous pre-market review to prove safety and efficacy before they ever hit the market.
The recent legal battle hinged on this distinction: is a test a distinct “service” (LDT) or a commercial “device” (FDA)?
Why LDTs Are Critical for Patient Care
When a new health threat emerges or a rare disease needs a specific biomarker tracked, patients simply cannot wait months (or years) for a commercial manufacturer to build, validate, and ship a mass-market kit. LDTs allow labs to bridge this gap immediately.
The COVID-19 Case Study: Agility in a Crisis The COVID-19 pandemic offered the starkest example of why LDTs are vital for patient survival.
- Speed: When the pandemic hit, commercial kits were non-existent or in critically short supply. LDTs allowed high-complexity labs to build their own PCR tests within weeks, providing the only diagnostic option for patients in the early months of 2020.
- Supply Chain Resilience: As global supply chains collapsed, labs with LDTs could rapidly re-validate their tests to use different reagents, swab types, or viral transport media. While commercial kits were “locked” to specific (and unavailable) supplies, LDTs allowed labs to adapt on the fly, ensuring testing didn’t grind to a halt.
- Local Precision: Every population is different. LDTs allow labs to tweak sensitivity to match specific local pathogen strains or variants that a standardized global kit might miss.
Innovation in Oncology This same agility applies to oncology, where labs use LDTs to target specific biomarkers for cancer treatments faster than the FDA approval pipeline can move. A notable example is the innovation from Exact Sciences, which has utilized LDTs—such as Cancerguard™ for multi-cancer early detection and Oncoguard® Liver for surveillance—to advance early detection years before a standardized kit could be mass-produced. Ultimately, this flexibility allows labs to stay agile, tailoring diagnostics to the specific demographics and needs of their local communities.
The Risks of Agility
However, this speed comes with risks. Without centralized FDA oversight, there is a concern that a lab’s internal validation might not be rigorous enough.
- The “Kit” Loophole: The FDA’s primary worry is large labs that act as unregulated manufacturers, creating kits and shipping them to other sites under the guise of being a local LDT.
- The “Black Box” Problem: Modern tests often rely on complex AI or software algorithms. Without external review, errors in the code can go undetected.
- Direct-to-Consumer (DTC) Confusion: If high-complexity tests are sold directly to patients without a doctor in the loop, people might misinterpret the results and make poor health decisions.
Impact of the Federal Court Ruling
The 2025 court ruling successfully dismantled the FDA’s aggressive four-year phaseout plan, relieving labs of the massive costs and paperwork once required for LDT approval. By classifying LDTs as professional services rather than medical devices, the court preserved laboratory autonomy but left a narrow definition that creates new challenges.
For instance, health systems may now be hesitant to share test logic or algorithms between their own “Lab A” and “Lab B,” as this could be legally reclassified as “distributing a device.” Moving forward, the FDA is expected to pivot from broad regulation to targeted enforcement, focusing on bad actors—specifically those selling risky Direct-to-Consumer tests or marketing manufactured kits under the LDT label.
What This Means for Beaker Implementations
Building and maintaining LDTs requires a significant shift in how a Laboratory Information System (LIS), such as Beaker, is managed. Because the lab assumes the role of the manufacturer, the LIS must move beyond simple result entry to become the primary engine for custom logic and compliance.
The primary impacts of LDTs on an LIS implementation include:
- Custom Workflow & Reflex Logic: Unlike standardized commercial kits, LDTs require the LIS to be configured from scratch to handle complex “if-then” scenarios and unique result formatting.
- Version Control & Validation History: The LIS must act as the source of truth, maintaining rigorous audit trails for every change to the test’s logic or code.
- Bioinformatic Integration: For oncology and genetics, the LIS must interface with specialized middleware to process massive datasets from NGS (Next-Generation Sequencing) pipelines.
- Mandatory Disclaimers: To comply with federal standards like 21 CFR 809.30(e), the LIS must be programmed to automatically append specific disclaimers to reports, clarifying that the test was developed by the lab and has not been FDA-cleared.
LDTs are the rapid-response unit of modern medicine. Whether it is responding to a global pandemic or advancing early cancer detection, the ability to innovate within the lab is a cornerstone of patient care. By combining clinical expertise with a robust, compliant LIS implementation, labs can deliver lifesaving answers when commercial options fail—balancing the need for speed with a steadfast commitment to patient safety.
Honeydew is very familiar with these complexities. We have a unique perspective on how various labs have navigated these transitions, from building custom reflex logic and creative solutions to maintain compliance. We understand that the challenge isn’t just following the law; it’s ensuring your LIS supports your scientists instead of slowing them down.
Interested in working with elite Beaker and DI consultants and/or learning more about Honeydew? Message info@honeydewconsulting.com to learn more.